| 8.03 1.94 (31.86%) | 07-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.73  |
1-year : | 29.36 |
| Resists | First : | 17.75 |
Second : | 25.13 |
| Pivot price | 12.27 |
|||
| Supports | First : | 5.8 | Second : | 4.82 |
| MAs | MA(5) : | 6.85 |
MA(20) : | 14.58 |
| MA(100) : | 24.68 |
MA(250) : | 20.62 |
|
| MACD | MACD : | -4.8 |
Signal : | -4.2 |
| %K %D | K(14,3) : | 6.2 |
D(3) : | 3.9 |
| RSI | RSI(14): 25 |
|||
| 52-week | High : | 69 | Low : | 5.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RGC ] has closed above bottom band by 29.0%. Bollinger Bands are 130.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.8 - 8.86 | 8.86 - 8.91 |
| Low: | 5.9 - 5.95 | 5.95 - 6 |
| Close: | 7.92 - 8.03 | 8.03 - 8.13 |
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Wed, 01 Jul 2026
Regencell Bioscience stock rebound leaves May share buyers deep underwater - TechStock²
Tue, 30 Jun 2026
RGC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
Fri, 26 Jun 2026
Regencell Bioscience (RGC) Sees Significant Drop in Stock Price - GuruFocus
Thu, 18 Jun 2026
RGC News | REGENCELL BIOSCIENCE HOLDING (NASDAQ:RGC) - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 494 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 88.3 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 752 (K) |
| Shares Short P.Month | 797 (K) |
| EPS | -0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -85 % |
| Return on Equity (ttm) | -177.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -803 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -992.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|